Mifepristone - VGX Pharmaceuticals

Drug Profile

Mifepristone - VGX Pharmaceuticals

Alternative Names: PICTOVIR; VGX-410; VGX-410C

Latest Information Update: 15 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VGX Pharmaceuticals
  • Class Abortifacients; Antiprogestogens; Antivirals; Dimethylamines; Estrenes; Oral contraceptives; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists; Hepatitis C internal ribosome entry site inhibitors; HIV pre-integration complex translocation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 02 Sep 2007 VGX Pharmaceuticals completes enrolment in the VT003 trial for Hepatitis C virus infections in the US
  • 21 Feb 2007 VGX 410 licensed to VGX International to sell and market in Asia and other developing regions, including Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top